{"id":14563,"date":"2023-08-30T01:05:00","date_gmt":"2023-08-29T17:05:00","guid":{"rendered":"https:\/\/flcube.com\/?p=14563"},"modified":"2024-11-24T01:15:18","modified_gmt":"2024-11-23T17:15:18","slug":"biocytogen-pharmaceuticals-eucure-biopharma-expands-partnership-with-syncromune-on-immunotherapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14563","title":{"rendered":"Biocytogen Pharmaceuticals&#8217; Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/2315:HKG\">HKG: 2315<\/a>) wholly owned subsidiary, Eucure Biopharma, has announced a technology transfer agreement with US firm Syncromune. This agreement builds upon an earlier licensing deal made in 2022, which resulted in Eucure transferring rights related to the drug candidate YH002 and other clinical stage antibodies to Syncromune after exercising its option. Under the new agreement, Syncromune will pay Eucure an undisclosed upfront payment and is committed to further milestone payments upon exercising its option.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Joint Development and Commercialization of Intratumoral Immunotherapies<\/strong><br>Eucure and Syncromune have agreed to jointly develop and commercialize intratumoral immunotherapies based on Syncromune&#8217;s proprietary Syncrovax technology. Syncromune will hold exclusive development and commercialization rights to the intratumoral immunotherapy composed of YH002 and other active pharmaceutical ingredients (APIs) to be applied to Syncrovax therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>YH002: A Monoclonal Antibody Targeting OX40<\/strong><br>YH002 is a monoclonal antibody (mAb) targeting OX40, which is under development as a SYNC-T-based intratumoral immunotherapy combined with other clinical antibodies. This approach aims to leverage the potential of intratumoral immunotherapies for treating cancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>SYNC-T: Syncromune&#8217;s Innovative Technology Platform<\/strong><br>Syncromune is developing SYNC-T, a disruptive personalized in situ technology platform designed to educate T cells and activate the immune system to treat previously untreatable metastatic solid tumors. SYNC-T utilizes a combination of tumor activation and targeted delivery methods to synchronize the spatiotemporal release of tumor antigens with the functional activation of immune cells, offering a new frontier in cancer immunotherapy.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd\u2019s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[1519,16,2297,1214,2298],"class_list":["post-14563","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biocytogen-pharmaceuticals","tag-cancer","tag-eucure-biopharma","tag-hkg-2315","tag-syncromune"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biocytogen Pharmaceuticals&#039; Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd\u2019s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced a technology transfer agreement with US firm Syncromune. This agreement builds upon an earlier licensing deal made in 2022, which resulted in Eucure transferring rights related to the drug candidate YH002 and other clinical stage antibodies to Syncromune after exercising its option. Under the new agreement, Syncromune will pay Eucure an undisclosed upfront payment and is committed to further milestone payments upon exercising its option.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14563\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen Pharmaceuticals&#039; Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14563\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-29T17:05:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-23T17:15:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14563#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14563\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen Pharmaceuticals&#8217; Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies\",\"datePublished\":\"2023-08-29T17:05:00+00:00\",\"dateModified\":\"2024-11-23T17:15:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14563\"},\"wordCount\":254,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biocytogen Pharmaceuticals\",\"Cancer\",\"Eucure Biopharma\",\"HKG: 2315\",\"Syncromune\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14563#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14563\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14563\",\"name\":\"Biocytogen Pharmaceuticals' Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-29T17:05:00+00:00\",\"dateModified\":\"2024-11-23T17:15:18+00:00\",\"description\":\"China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd\u2019s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced a technology transfer agreement with US firm Syncromune. This agreement builds upon an earlier licensing deal made in 2022, which resulted in Eucure transferring rights related to the drug candidate YH002 and other clinical stage antibodies to Syncromune after exercising its option. Under the new agreement, Syncromune will pay Eucure an undisclosed upfront payment and is committed to further milestone payments upon exercising its option.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14563#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14563\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14563#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen Pharmaceuticals&#8217; Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen Pharmaceuticals' Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd\u2019s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced a technology transfer agreement with US firm Syncromune. This agreement builds upon an earlier licensing deal made in 2022, which resulted in Eucure transferring rights related to the drug candidate YH002 and other clinical stage antibodies to Syncromune after exercising its option. Under the new agreement, Syncromune will pay Eucure an undisclosed upfront payment and is committed to further milestone payments upon exercising its option.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14563","og_locale":"en_US","og_type":"article","og_title":"Biocytogen Pharmaceuticals' Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14563","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-29T17:05:00+00:00","article_modified_time":"2024-11-23T17:15:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14563#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14563"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen Pharmaceuticals&#8217; Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies","datePublished":"2023-08-29T17:05:00+00:00","dateModified":"2024-11-23T17:15:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14563"},"wordCount":254,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biocytogen Pharmaceuticals","Cancer","Eucure Biopharma","HKG: 2315","Syncromune"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14563#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14563","url":"https:\/\/flcube.com\/?p=14563","name":"Biocytogen Pharmaceuticals' Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-29T17:05:00+00:00","dateModified":"2024-11-23T17:15:18+00:00","description":"China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd\u2019s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced a technology transfer agreement with US firm Syncromune. This agreement builds upon an earlier licensing deal made in 2022, which resulted in Eucure transferring rights related to the drug candidate YH002 and other clinical stage antibodies to Syncromune after exercising its option. Under the new agreement, Syncromune will pay Eucure an undisclosed upfront payment and is committed to further milestone payments upon exercising its option.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14563#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14563"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14563#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen Pharmaceuticals&#8217; Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14563"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14563\/revisions"}],"predecessor-version":[{"id":14566,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14563\/revisions\/14566"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}